
Peptide Synthesis Market to Hit USD 1.41 Billion by 2029 with 11.7% CAGR
"Thermo Fisher Scientific Inc. is one of the dominant players in the peptide synthesis market. The company's leading position is attributable to its diversified product portfolio, strong geographic presence, and adoption of various growth strategies."
The market for peptide synthesis market is competitive, with key players strategizing to capture the majority market share. Prominent players in the peptide synthesis market are Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Agilent Technologies Inc. (US), Kaneka Corporation (Japan), GenScript (China)
The Peptide Synthesis market valued at US$ 0.78 Billion in 2023, is forecasted to grow at a robust CAGR of 11.7%, reaching US$ 0.81 Billion in 2024 and an impressive US$ 1.41 Billion by 2029. The peptide synthesis market is driven by the growing demand for therapeutic peptides in treating chronic diseases, including cancer, diabetes, and cardiovascular disorders. Advancements in solid-phase peptide synthesis (SPPS) and hybrid approaches have significantly improved efficiency, yield, and cost-effectiveness, fueling adoption in pharmaceutical R&D. The rise of personalized medicine has further expanded the need for custom peptide synthesis, supporting applications in targeted therapies and biomarker research. Emerging trends such as the integration of automation and AI-driven platforms among the instruments is further likely to fuel the market growth in coming years.
Browse in-depth TOC on " Peptide Synthesis Market"
513 - Tables
55 - Figures
460 - Pages
Based on offerings, the market is segmented into products and services. By-products market is further divided into consumables and instruments. Among these consumables dominated the peptide synthesis market. The consumables segment is further bifurcated into reagents and other consumables. The reagents market is further divided into resins, amino acids, coupling reagents, dyes & fluorescent labeling reagents, deprotection agents, cleavage reagents, and other reagents. In 2023, the resins segment accounted for the largest share of the peptide synthesis market. Resins play an important role in solid-phase peptide synthesis (SPPS), the most widely used method for peptide production. For instance, polystyrene-based and PEG-based resins are extensively used due to their high stability and scalability.
The instruments segment is further divided into peptide synthesizers, chromatography equipment, lyophilizers, and others. The peptide synthesizer segment is further divided into automated and manual peptide synthesizers. Peptide synthesizers dominated the instruments market due to their ability to automate and streamline peptide production, making them essential for research and industrial applications. The growing demand for custom peptides in drug discovery, diagnostic research, and therapeutic applications has further boosted the adoption of advanced synthesizers.
The services segment is further divided into peptide library synthesis, peptide synthesis, peptide purification services, and peptide analysis services. The peptide synthesis segment dominated the services segment. The increasing adoption of peptides in emerging fields such as personalized medicine, vaccine development, and epigenetics drives demand for custom synthesis solutions, fostering growth in the segment.
Based on technique, the peptide synthesis market is segmented into chemical and biological. The chemical segment is further divided into solid-phase peptide synthesis, solution-phase peptide synthesis, and others. The biological segment is divided into recombinant DNA technology and enzymes. The chemical segment dominated the market in 2023. The solid-phase peptide synthesis (SPPS) segment dominates the peptide synthesis market due to its efficiency, scalability, and widespread adoption in research and commercial applications. The dominance of SPPS is further driven by advancements in automation and reagent technologies, which have significantly reduced synthesis time and enhanced yield.
Based on application, the market is divided into therapeutics, diagnostics, and research & development. Therapeutics by indication is further divided into cancer, diabetes, obesity, autoimmune disease, and other disease indications. Therapeutics by molecules is further segmented into peptide-based vaccines, peptide-drug conjugates (PDCs), peptide inhibitors, and other molecules. Therapeutic applications dominated the peptide synthesis market due to the growing demand for peptide-based drugs, which offer targeted and effective treatments with fewer side effects compared to traditional small molecules.
The peptide synthesis market is segmented by end users into pharmaceutical and biotechnology companies, CDMOS & CROS, academic and research institutes, medical device companies, and hospitals and diagnostic centers. The pharmaceutical and biotechnology companies segment held the largest market share in 2023. The rise of peptide-based drugs and biologics has led to increased investments by pharmaceutical and biotech firms in peptide synthesis technologies, particularly in the production of therapeutic peptides for diseases such as cancer, diabetes, and autoimmune disorders. These factors are fueling the growth of the segment.
The market is segmented by region into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America dominated the peptide synthesis market in 2023, and the Asia Pacific region is likely to grow at a significant CAGR during the forecast period. US-dominated North American peptide synthesis market owing to the presence of strong pharmaceutical and biotechnology companies in the country, advanced research infrastructure, and significant investments in drug discovery and development. The Asia Pacific region is anticipated to grow at a significant CAGR due to growing focus on personalized medicine and peptide-based therapeutics in the region fuels the demand for advanced peptide synthesis technologies.
The market for peptide synthesis market is competitive, with key players strategizing to capture the majority market share. Prominent players in the peptide synthesis market are Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Agilent Technologies Inc. (US), Kaneka Corporation (Japan), GenScript (China), and Bachem Holding AG (Switzerland), among others. The market players have adopted various organic and inorganic growth strategies, such as the development of advanced products, partnerships, agreements, expansions, and acquisitions to strengthen their position in the peptide synthesis market.
Thermo Fisher Scientific Inc. is one of the dominant players in the peptide synthesis market. The company's leading position is attributable to its diversified product portfolio, strong geographic presence, and adoption of various growth strategies. The company offers a wide range of peptide synthesis products and services. The company has adopted different growth strategies, such as deals that include agreements, and acquisitions, to maintain its leading position in the peptide synthesis market. The company's strong customer support and extensive distribution network further solidify the company's leadership position in the market.
Merck KGaA is a key player in the peptide synthesis market, leveraging its expertise in life sciences and advanced chemical technologies. The company's Novabiochem product line offers a broad range of high-quality reagents, resins, and building blocks essential for efficient and reliable peptide synthesis. Merck KGaA focuses on innovation supporting advanced techniques such as microwave-assisted synthesis, which significantly improves reaction efficiency and yield. The company's strategic partnerships and increased investments in biopharmaceutical R&D further enhance its competitive edge in the market. Merck's strong geographic presence and adoption of growth strategies further contribute to its dominance in the market.
For more information, Inquire Now!
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

National Post
2 hours ago
- National Post
Toshiba Releases 2-Channel Automotive Standard Digital Isolators Compliant with AEC-Q100
Article content – Realize Stable Operation with High Common-mode Transient Immunity and High-Speed Data Communication – Article content KAWASAKI, Japan — Toshiba Electronic Devices & Storage Corporation ('Toshiba') has launched a line of 2-channel high-speed standard digital isolators for automotive applications. The new 'DCM32xx00 Series' features four devices that support stable operation with high common-mode transient immunity (CMTI) of 100kV/μs (typ.) [1] and high data transmission rate of 50Mbps (max) [2]. All conform to the AEC-Q100 standard for the safety and reliability of automotive electronic components. Shipments start today. Article content The safety and reliability of on-board chargers (OBC) and battery management systems (BMS) in hybrid-electric vehicles (HEV) and electric vehicles (EV) require devices that ensure isolation and prevent noise-propagation. Automotive standard digital isolators provide solutions for the multi-channel high-speed communications and high CMTI these isolation devices require. Article content The new isolators use Toshiba's proprietary magnetic coupling type isolated transmission method to achieve a high CMTI of 100kV/μs (typ.). This delivers high level resistance to electric noise between input and output in isolated signal transmission, enables stable control signal transmission and contributes to stable equipment operation. A low-pulse-width distortion of 0.8ns (typ.) [2] and a data-transmission rate of 50Mbps (max) [2] are also achieved. The new products are suitable for 2-channel high-speed communication applications such as I/O interfaces with CAN [3] communications. Article content Toshiba already mass produces 4-channel automotive standard digital isolators, and has now extended its product lineup to 2-channel small SOIC8-N packages. Going forward, the company will expand its range of channels and packages for automotive and industrial equipment. It will continue to provide high-quality isolation devices and photocouplers that support the reliability and real-time data transmission required by automotive equipment. Article content [1] Test conditions: VDD1=VDD2=4.5 to 5.5V, VCM=1500V, T opr =-40 to 125°C [2] Test conditions: VDD1=VDD2=4.5 to 5.5V, T opr =-40 to 125°C [3] CAN (Controller Area Network): A serial communications standard, primarily used for automotive communication networks. Article content Automotive equipment Article content Features Article content High common mode transient immunity: CMTI=100kV/μs (typ.) [1] High-speed data rate: t bps =50Mbps (max) [2] Low pulse width distortion: PWD=0.8ns (typ.) [2] 2-channel support (see Main Specifications for details on each device): One forward channel and one reverse channel; Two forward channels and no reverse channel Article content Main Specifications (Unless otherwise specified, T opr =-40 to 125°C) Part number DCM321C00 DCM321D00 DCM320C00 DCM320D00 Number of channels (Forward directions: reverse directions) 2 (1:1) 2 (2:0) Default Output Low High Low High Input/Output Control None Package SOIC8-N Absolute Maximum Ratings Operation temperature range T opr (°C) -40 to 125 Storage temperature range T stg (°C) -65 to 150 Isolation voltage BV S (Vrms) t=1min, Ta=25°C Min 3000 Electrical Characteristics Common- Mode Transient Immunity CMTI (kV/μs) V DD1 =V DD2 = 4.5 to 5.5V, V CM =1500V Typ. 100 Data Rate t bps (Mbps) V DD1 =V DD2 = 4.5 to 5.5V Max 50 Pulse Width Distortion PWD (ns) Typ. 0.8 Propagation Delay t PHL, t PLH (ns) 10.9 Sample Check & Availability Buy Online Buy Online Buy Online Buy Online Article content Related information Article content Application Notes Article content Follow the links below for more on the new products. DCM321C00 DCM321D00 DCM320C00 DCM320D00 Follow the link below for more on Toshiba's standard digital isolators Standard Digital Isolators To check availability of the new products at online distributors, visit: DCM321C00 Buy Online DCM321D00 Buy Online DCM320C00 Buy Online DCM320D00 Buy Online * Company names, product names, and service names may be trademarks of their respective companies. * Information in this document, including product prices and specifications, content of services and contact information, is current on the date of the announcement but is subject to change without prior notice. Article content Toshiba Electronic Devices & Storage Corporation, a leading supplier of advanced semiconductor and storage solutions, draws on over half a century of experience and innovation to offer customers and business partners outstanding discrete semiconductors, system LSIs and HDD products. Article content Its 19,400 employees around the world share a determination to maximize product value, and to promote close collaboration with customers in the co-creation of value and new markets. The company looks forward to building and to contributing to a better future for people everywhere. Article content Article content Article content Article content Contacts Article content Customer Inquiries Article content Article content Optoelectronic Device Sales & Marketing Dept. Article content Article content Tel: +81-44-548-2218 Article content Article content Contact Us Article content Media Inquiries Article content Article content Chiaki Nagasawa Article content Article content Digital Marketing Dept. Article content Article content Article content

National Post
2 hours ago
- National Post
New Murata Automotive-Compliant Chip Ferrite Beads Deliver Wide Band Noise Suppression of High-Frequency (5.9GHz) C-V2X
Article content The new BLM15VM series is ideal for automotive powertrains and safety applications. It supports high frequencies. 1000Ω (Typ.) @5.9GHz. With its compact 0402-inch size (1.0×0.5mm) can operate at temperatures ranging from -55 to 150°C. And it is compliant with AEC-Q200. Article content KYOTO, Japan — Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) continues to push the envelope in automotive noise suppression technology with another industry first. By leveraging proprietary material technology and optimized structural design, the company's new BLM15VM series of automotive-compliant chip ferrite beads deliver wide-band noise suppression of high-frequency (5.9GHz) 5G vehicle-to-everything (5G-V2X) applications that exhibit high impedance. Mass production is scheduled to begin in July 2025. Article content Article content In recent years, the use of high-frequency wireless communication in the automotive sector has increased. It is primarily used for content distribution for navigation, audio and other infotainment systems. Improving sensitivity and noise suppression in these advanced high-frequency communication systems becomes mission critical to support the connected car for ADAS (Advanced Driver Assistance Systems) and eventually autonomous driving. Article content RF inductors typically used for noise suppression in sub-6GHz communication have a narrow frequency band at high impedance, making it necessary to select components that match the noise frequency band. With its broad high-frequency band at high impedance, the BLM15VM series allows easy noise suppression across multiple frequency bands using just one product. Even at 5.9GHz, the chip ferrite beads within the series will typically attain impedance values of 1000Ω. Article content By enabling error-free high-frequency communication, which is crucial for autonomous driving, the BLM15VM series significantly improves reception sensitivity in V2X communication in the 5.9GHz bands for autonomous driving and stable operation of dedicated short-range communication (DSRC) based control systems, operating in the 5.8GHz band, for improved road safety. Additionally, since Wi-Fi 6E and Wi-Fi 7, the communication standards for wireless LAN, also use the sub-6GHz band, this product can improve sensitivity and suppress noise in consumer communication devices. Article content The AEC-Q200-compliant BLM15VM series of chip ferrite beads from Murata supports operating temperatures between -55 to 150°C and is supplied in a compact 0402-inch size (1.0×0.5mm). Murata is committed to expanding its lineup to meet market needs. Article content Editor's Notes Article content According to the Company's research. This is the world's first product that removes noise in high-frequency communication (including Sub6 bands) for C-V2X, as of June 18, 2025. Article content About Murata Article content Murata Manufacturing Co., Ltd. is a worldwide leader in the design, manufacture and sale of ceramic-based passive electronic components & solutions, communication modules and power supply modules. Murata is committed to the development of advanced electronic materials and leading edge, multi-functional, high-density modules. The company has employees and manufacturing facilities throughout the world. Article content Article content Article content Article content Article content Article content


Globe and Mail
5 hours ago
- Globe and Mail
Drug Discovery Platforms Market Projected to Reach USD 512.9 Mn by 2032 with 13.5% CAGR
Drug Discovery Platforms Market, By Drug Type (Small Molecule and Large Molecule), By Technology (Genomics, Proteomics, Cell-Based Assays, High-Throughput Screening, Bioinformatics, Next-Generation Sequencing, Mass Spectrometry, Imaging Technologies, Microfluidics, and Artificial Intelligence & Machine Learning), By Therapeutic Area (Oncology, Neurology, Infectious And Immune System Diseases, Digestive System Diseases, Cardiovascular Diseases, Diabetes, Respiratory Disease) Drug Discovery Platforms Market Insights The drug discovery platforms industry is experiencing robust expansion fueled by technological innovation and rising R&D investments. Experts are leveraging high-throughput screening, AI-driven modeling, and advanced microfluidics to accelerate candidate identification. This blog synthesizes our data-backed market insights, with actual instances from 2024–2025. The Global Drug Discovery Platforms Market size is estimated to be valued at USD 211.3 Mn in 2025 and is expected to reach USD 512.9 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 13.5% from 2025 to 2032. Request Sample Copy of this Report (Use Corporate eMail ID to Get Higher Priority) at: Market Key takeaways: • North America: Leading in AI-integrated screening, driven by biopharma hubs in Boston and San Francisco. • Latin America: Growing collaboration with academic centers in Brazil and Mexico fueling assay development. • Europe: Strong government grants in the UK, Germany, and Switzerland supporting genomics platforms. • Asia Pacific: Rapid CDMO expansion in China and India boosting microfluidics deployments. • Middle East: Investments in precision medicine initiatives across GCC states. • Africa: Emerging research consortia in South Africa adopting cloud-based virtual screening. Market Segmentation: • Platform Type: – High-throughput screening (HTS): Enables 100K+ compound tests/week; used by major pharma. – Virtual screening: AI-driven docking reduced lead time by 20% in 2024 for a European biotech. – Microfluidics: Droplet-based chips processed 1M reactions/month in a 2025 pilot program in Japan. • Technology: – Genomics: NGS-based target validation grew 18% adoption in 2024 for oncology R&D. – Proteomics: Mass-spec arrays identified 500+ biomarkers in 2025 diabetes trials. – Imaging: High-content confocal microscopy expanded throughput by 30% in a US CRO. • End User: – Pharmaceutical & Biotech: Outsourced 65% of initial screening in 2024 to specialized platforms. – Academic Research: Published 150+ discovery papers using integrated platforms last year. – Contract Research Organizations: Launched 12 new service offerings in 2025 for fragment libraries. Growth Factors: • Rising R&D spend: Global pharma R&D climbed to USD 200 Bn in 2024, driving demand for automated assays. • AI and ML integration: Adoption of AI-driven predictive analytics increased by 25% among top 20 biotech firms in 2024. • Personalized medicine push: Over 400 companion diagnostics in pipeline at end-2025, expanding platform scope. • Government grants: A EUR 100 M EU grant in 2024 accelerated genomics-based discovery in academic spin-offs. Book the Latest Edition of this Market Study Get Up to 25 % Discount: Market Trends: • Consolidation: M&A activity saw 10 platform mergers in 2024, enhancing service portfolios. • Cloud-based workflows: 50% of new platforms in 2025 migrated screening data to secure cloud, improving collaboration. • Fragment-based design: Usage rose to 35% of total screening budgets in 2025 versus 22% in 2023. • Sustainability: Reagent recycling initiatives reduced assay waste by 15% in leading North American labs in 2024. Actionable Insights: • Production Capacity: Over 10 Bn assays capacity in global HTS facilities by 2025—up 18% since 2023. • Pricing Dynamics: Average per-assay cost dropped from USD 3.20 in 2023 to USD 2.75 in 2024, widening market opportunities. • Exports: Asia Pacific platforms exported USD 150 M worth of microfluidic chips in 2024, growing 30% YoY. • Imports: North America imported USD 120 M of high-content imaging modules in 2025, up 22% from 2024. • Use Cases: Oncology screening accounted for 40% of demand, neurology 18%, and infectious disease 12% in 2024. • Nano Indicators: Adoption of droplet microarrays reached 28% penetration in US academic labs by 2025. Key Players: • Thermo Fisher Scientific • Agilent Technologies • Danaher Corporation • PerkinElmer • Merck KGaA • Roche Holding AG • QIAGEN • Bruker Corporation • Bio-Rad Laboratories • Illumina • Charles River Laboratories • Evotec • WuXi AppTec • Schrödinger • Abcam Get Customization on this Report: Competitive Strategies: • Schrödinger's 2024 partnership with a top 10 pharma accelerated lead optimization by 30%, boosting its ROI by 18%. • Illumina's pricing strategy—introducing a tiered subscription for genomic assays—grew recurring revenue by 22% in FY 2024. • Thermo Fisher's acquisition of a microfluidics startup in mid-2025 expanded its market scope, adding USD 50 M in annual revenue. Frequently Asked Questions 1. Who are the dominant players in the Drug Discovery Platforms market? Key players include Thermo Fisher Scientific, Agilent Technologies, Danaher Corporation, PerkinElmer, Merck KGaA, Roche, QIAGEN, Bruker, Bio-Rad, Illumina, Charles River, Evotec, WuXi AppTec, Schrödinger, and Abcam. 2. What will be the size of the Drug Discovery Platforms market in the coming years? The market is projected to grow from USD 211.3 Mn in 2025 to USD 512.9 Mn by 2032 at a CAGR of 13.5%. 3. Which end-users industry has the largest growth opportunity? Pharmaceutical & biotech firms lead demand, followed by academic research and CROs, driven by high-throughput and AI-enabled workflows. 4. How will market development trends evolve over the next five years? Key trends include AI/ML convergence, sustainability in reagent use, cloud-based data management, and fragment-based design. 5. What is the nature of the competitive landscape and challenges in the Drug Discovery Platforms market? Competition centers on technological integration, pricing competitiveness, and partnerships; challenges involve data security, regulatory compliance, and reagent supply constraints. 6. What go-to-market strategies are commonly adopted in the Drug Discovery Platforms market? Strategies include M&A for portfolio expansion, subscription-based assay models, strategic partnerships for co-development, and tiered pricing to penetrate emerging regions. About Coherent Market Insights Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.